- Trial phase
- Phase 2
- Time to market
- If Phase 2 data are positive, Phase 3 trials would likely follow, with a potential BLA filing and launch estimated around 2031-2033 per analyst estimates.
- Why 6/10
- The next hard catalyst is the 16-week topline data from the ORCA-SURGE Phase 2 trial in moderate-to-severe plaque psoriasis, expected in 1Q 2027 (roughly 4-5 months from today). ORKA-002 is the company's second program behind lead asset ORKA-001, so the readout is important but not make-or-break for the company, which has a $1.1B cash position and multiple pipeline assets.
The next hard catalyst for ORKA-002 is the 16-week topline data from the ORCA-SURGE Phase 2 trial in moderate-to-severe plaque psoriasis, expected in 1Q 2027. Positive efficacy and safety data would validate the IL-17A/F platform and support advancement toward Phase 3, while disappointing results could pressure the stock given the high expectations baked into the current valuation.
Price Chart
Executive Summary
ORKA-002 is Oruka Therapeutics' second pipeline asset, a half-life extended anti-IL-17A/F monoclonal antibody for chronic skin diseases including plaque psoriasis and hidradenitis suppurativa. Phase 1 data showed a 75-80 day half-life supporting twice-per-year dosing, and a Phase 2 trial (ORCA-SURGE) in psoriasis is underway with 16-week results expected in 1Q 2027. The company's lead asset ORKA-001 has generated strong Phase 2b data, and Oruka holds roughly $1.1B in cash. The stock trades near $105, up sharply from its 52-week low of $25, with a mean analyst price target of $156 implying 52% upside. ORKA-002 has no reported efficacy data yet and faces a crowded IL-17 inhibitor market.
How It Works
ORKA-002 is a monoclonal antibody (a lab-made protein that mimics the immune system's ability to fight targets) designed to block two related inflammatory signals called IL-17A and IL-17F. These signals drive the skin inflammation and plaque formation seen in psoriasis and related conditions like hidradenitis suppurativa. The drug is engineered with a half-life extension technology so it stays in the body much longer than existing IL-17 blockers, potentially allowing patients to receive injections only two to four times per year instead of monthly.
Trial Status
Phase 1 completed with positive interim data (75-80 day half-life). The ORCA-SURGE Phase 2 trial in moderate-to-severe plaque psoriasis was initiated in March 2026 and is actively enrolling. A separate Phase 2 trial in hidradenitis suppurativa (ORCA-SPLASH) is also planned. The 16-week topline data from ORCA-SURGE are expected in 1Q 2027.
The Two-Sided Case
Upcoming Catalysts
- ORCA-SURGE Phase 2 16-week topline results in moderate-to-severe plaque psoriasis expected 1Q 2027
- ORCA-SPLASH Phase 2 trial initiation in hidradenitis suppurativa (timing TBD)
- Potential advancement to Phase 3 if Phase 2 data are positive
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Oruka Therapeutics, Inc. PRESS-RELEASE ORKA ·Originating report